Bulletin de la Societe belge d'ophtalmologie · 2003
[Treatment of Graves macular edema with intravitreal injection of corticosteroids].
Оценочное исследованиеСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Rakic J M, Zelinkova M, Comhaire-Poutchinian Y, Galand A, Duchateau E
Аннотация
PURPOSE: To determine if intravitreal injection of triamcinolone is an effective option in treating severe macular oedema unresponsive to other treatments.
METHODS: Fifteen eyes with severe macular oedema of long duration (9-30 months) were offered intravitreal injection of 4 mg triamcinolone. The visual acuity and anatomic responses were monitored with pre- and postoperative fluorescein angiography and optical coherence tomography (OCT).
RESULTS: The minimal follow-up was 3 months (mean = 6 months). The central macular thickness evaluated by OCT decreased by 50%. This beneficial effect was correlated with a significant improvement in visual acuity. Ten of 15 patients (66%) improved their visual acuity by more than two Snellen lines. We could observe a significant increase in intraocular pressure (mean = 15%) due to corticosteroid medication. No injection-related complication occurred. One patient had to be retreated after 3 months due to recurrence of macular oedema.
CONCLUSIONS: Intravitreal triamcinolone is a promising therapeutic option for severe macular oedema. Further study is warranted to evaluate the long-term efficacy and safety, as well as the need for retreatment.
METHODS: Fifteen eyes with severe macular oedema of long duration (9-30 months) were offered intravitreal injection of 4 mg triamcinolone. The visual acuity and anatomic responses were monitored with pre- and postoperative fluorescein angiography and optical coherence tomography (OCT).
RESULTS: The minimal follow-up was 3 months (mean = 6 months). The central macular thickness evaluated by OCT decreased by 50%. This beneficial effect was correlated with a significant improvement in visual acuity. Ten of 15 patients (66%) improved their visual acuity by more than two Snellen lines. We could observe a significant increase in intraocular pressure (mean = 15%) due to corticosteroid medication. No injection-related complication occurred. One patient had to be retreated after 3 months due to recurrence of macular oedema.
CONCLUSIONS: Intravitreal triamcinolone is a promising therapeutic option for severe macular oedema. Further study is warranted to evaluate the long-term efficacy and safety, as well as the need for retreatment.